{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:49:19Z","timestamp":1782928159134,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ad.2026.104634","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:17:14Z","timestamp":1774023434000},"page":"104634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experience With Rituximab in Patients With Pemphigus Vulgaris and Hepatitis B"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2406-946X","authenticated-orcid":false,"given":"R.","family":"Collado Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-7864","authenticated-orcid":false,"given":"O.L.","family":"Forero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-7563","authenticated-orcid":false,"given":"M.E.","family":"Candiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-5160","authenticated-orcid":false,"given":"S.","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-2560","authenticated-orcid":false,"given":"S.","family":"Lloveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-7731","authenticated-orcid":false,"given":"J.","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2026.104634_bib0090","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ad.2026.104634_bib0095","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"French Study Group on Autoimmune Bullous Diseases. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2026.104634_bib0100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2026.104634_bib0105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2026.104634_bib0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4103\/ijd.ijd_169_22","article-title":"Experience of rituximab therapy in pemphigus: a three-year retrospective study from a sub-Himalayan state","volume":"67","author":"Verma","year":"2022","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.ad.2026.104634_bib0115","first-page":"305","article-title":"Rituximab como primera l\u00ednea de tratamiento en p\u00e9nfigo moderado. Dermatosis ampollares autoinmunes: Haga su diagn\u00f3stico.1\u00aaed","author":"Forero","year":"2022","journal-title":"J Ciud Aut\u00f3n Buenos Aires"},{"key":"10.1016\/j.ad.2026.104634_bib0120","first-page":"1","article-title":"Gu\u00edas de manejo de penfigoide ampollar","volume":"1","author":"Candiz","year":"2021","journal-title":"Soc Argent Dermatol"},{"key":"10.1016\/j.ad.2026.104634_bib0125","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20912646","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations","author":"Koutsianas","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ad.2026.104634_bib0130","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ad.2026.104634_bib0135","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.3748\/wjg.v20.i37.13293","article-title":"Update on hepatitis B virus infection","volume":"20","author":"You","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2026.104634_bib0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult to manage autoimmune hepatitis: results from the International Autoimmune Hepatitis Group","volume":"1","author":"Ni Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ad.2026.104634_bib0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of Hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ad.2026.104634_bib0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2026.104634_bib0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MCG.0000000000001520","article-title":"Hepatitis B reactivation: a review of clinical guidelines","volume":"55","author":"Wang","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ad.2026.104634_bib0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2026.104634_bib0165","series-title":"Dermatosis ampollares autoinmunes: haga su diagn\u00f3stico","first-page":"302","article-title":"Penfigo e infecci\u00f3n cr\u00f3nica por hepatitis B","author":"Forero","year":"2022"},{"key":"10.1016\/j.ad.2026.104634_bib0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2019.10.017","article-title":"Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab","volume":"6","author":"Yoo","year":"2020","journal-title":"JAAD Case Rep"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102600044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102600044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:16:27Z","timestamp":1782926187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102600044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S000173102600044X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2026.104634","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience With Rituximab in Patients With Pemphigus Vulgaris and Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2026.104634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104634"}}